RGBP · Regen BioPharma Inc · Executive Compensation
$0.00
+0.00 (+0.00%)
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 17, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements.”View the 10-Q filed Aug 17, 2026
Market Cap
$335,055
Shares
1.68B
Volume · Nov 6
3.62M
Avg daily vol (3M)
7.96M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Leadership
- David R. Koos CEO, Chairman